EcoDrugPlus

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSOMEG00000019139
Gene Symbol: CYP3A65
1 Cross references
539 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSOMEG00000021856
Gene Symbol: CYP3A65
1 Cross references
540 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSOMEG00000010711
Gene Symbol: LOC112144105
3 Cross references
179 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSOMEG00000013467
Gene Symbol: LOC112159316
3 Cross references
188 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSOMEG00000010781
Gene Symbol: LOC112147536
3 Cross references
197 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSOMEG00000021081
Gene Symbol: LOC112160987
3 Cross references
191 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSOMEG00000011981
Gene Symbol: DGAT1
3 Cross references
191 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSOMEG00000003914
Gene Symbol: LOC112143225
3 Cross references
190 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSOMEG00000018454
Gene Symbol: DHODH
3 Cross references
172 Possible Orthologues:

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSOMEG00000017058
Gene Symbol: DPYD
3 Cross references
211 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSOMEG00000010222
Gene Symbol: DDR2
3 Cross references
190 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSOMEG00000002398
Gene Symbol: DDR2
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).